SFTPB Human

Surfactant Protein B (SP-B) is a crucial component of the pulmonary surfactant system, which is essential for normal respiratory function. The human recombinant form of SP-B is a synthetic version produced through recombinant DNA technology, which allows for the study and therapeutic use of this protein.

SP-B is an amphipathic protein, meaning it contains both hydrophilic (water-attracting) and hydrophobic (water-repelling) regions. This unique structure enables SP-B to interact with the lipid components of the pulmonary surfactant, a complex mixture of lipids and proteins that reduces surface tension in the lungs . By lowering surface tension, SP-B helps maintain alveolar stability, preventing the collapse of alveoli during exhalation and ensuring efficient gas exchange .

The gene encoding SP-B is known as SFTPB (Surfactant Protein B gene). Mutations in this gene can lead to surfactant metabolism dysfunction, which is associated with severe respiratory conditions such as hereditary pulmonary alveolar proteinosis and neonatal respiratory distress syndrome . These conditions highlight the critical role of SP-B in lung function and homeostasis.

Human recombinant SP-B is produced using recombinant DNA technology, which involves inserting the SFTPB gene into a suitable expression system, such as bacteria or yeast. This allows for the large-scale production of SP-B, which can be purified and used for research or therapeutic purposes .

The therapeutic potential of human recombinant SP-B is significant, particularly for treating respiratory conditions caused by surfactant deficiency. For example, recombinant SP-B can be administered to premature infants with underdeveloped lungs to improve their respiratory function and reduce the risk of respiratory distress syndrome . Additionally, research into SP-B and its interactions with other surfactant proteins and lipids continues to provide valuable insights into lung biology and disease mechanisms.